The FDA’s Rare Disease Innovation Hub (Hub) has released its Strategic Agenda, detailing its first-year actions and engagement with the rare disease community while clarifying its structure and programs. The Hub fosters collaboration between the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) to enhance rare disease […]
Read MoreFebruary 24, 2025
Research Progress Related to albinism
Research on albinism is crucial for improving the quality of life, health, and social inclusion of individuals with this condition. By studying the genetic causes and visual impairments associated with albinism, such as nystagmus and reduced melanin affecting vision and skin protection, researchers can develop targeted treatments and interventions. Advances in understanding albinism also help […]
Read MoreDecember 8, 2024
Research Progress Related to Vitiligo
Research on vitiligo provides significant benefits, advancing understanding of this complex autoimmune skin condition that causes patches of skin to lose pigment. By investigating the genetic, immunological, and environmental factors involved, researchers can develop more effective treatments and potential cures, improving quality of life for those affected. Additionally, research helps to raise awareness, reduce stigma, […]
Read MoreDecember 8, 2024